Understanding the Role of Polygenic Risk Scores in Breast Cancer
In a recent study conducted with the Department of Biomedicine and Prevention, Veritas Genetics has unveiled the significance of polygenic risk scores (PRS) in managing breast cancer patients. This innovative research underscores how PRS can enhance the risk stratification process for women with genetic predispositions to breast cancer.
Key Insights from the Innovative Study
The pilot study, led by Professor Giuseppe Novelli, showcases the collaborative efforts of Veritas' medical-scientific team, including notable professionals like Dr. Vincenzo Cirigliano and Dr. Luis Izquierdo. The research highlights that integrating PRS with the evaluation of pathogenic variants leads to a more refined risk assessment for women. This approach is particularly valuable for those who might not carry mutations in the commonly associated genes such as BRCA1 and BRCA2.
Significance of Polygenic Risk Scores
This extensive evaluation, published in the Journal of Personalized Medicine, illustrates that PRS notably enhances the precision of risk predictions. For women who have a family history of breast cancer but do not exhibit mutations in specific susceptibility genes, PRS can provide critical insights into their risk profile. For those who are carriers of such mutations, PRS complements existing evaluations, guiding individualized management strategies.
Transforming Cancer Assessment
Dr. Izquierdo, the Chief Medical Officer at Veritas, emphasizes the clinical value offered by genomic tools like PRS in preventive healthcare. He states, "The integration of PRS with traditional genetic assessments enables healthcare providers to deliver care that is not only more precise but also tailored to the unique needs of each patient. This customized approach can significantly improve long-term health outcomes for individuals at risk of developing breast cancer."
The Vision for Personalized Medicine
PRS stands at the forefront of a transformative shift in how cancer risks are evaluated. Dr. Izquierdo reiterates the capability of polygenic risk scoring to redefine our understanding of genetic susceptibility, especially within families affected by cancer. He notes that PRS is an essential tool in the advancement of personalized medicine, providing a proactive avenue for addressing complex conditions like breast cancer.
About Veritas Genetics
Veritas Genetics is committed to pioneering advanced genomic solutions that focus on both preventive and personalized medicine. Through strategic partnerships with leading academic institutions, the company continues to spearhead innovations that aim to enhance health outcomes and overall well-being.
Frequently Asked Questions
What are polygenic risk scores?
Polygenic risk scores (PRS) assess the cumulative effect of multiple genetic variants to predict an individual's risk for certain diseases, like breast cancer.
How does PRS benefit breast cancer patients?
PRS greatly enhances the accuracy of risk prediction, which helps healthcare professionals tailor prevention and management strategies for individual patients.
Who conducted the study on PRS and breast cancer?
The study was conducted by Veritas Genetics in collaboration with the Department of Biomedicine and Prevention at the University of Rome Tor Vergata and Tor Vergata University Hospital.
What is the significance of the study's findings?
The findings indicate that PRS can improve risk evaluations, particularly for women with a family history of breast cancer and those without pathogenic gene mutations.
How does Veritas Genetics contribute to personalized medicine?
Veritas Genetics leads advancements in genomic solutions that focus on customizing healthcare approaches to improve patient outcomes and wellbeing.
